Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Kennedy spotlights West Nile virus: Pathogen inactivation technology deemed "promising" in written remarks from Sen. Edward Kennedy (D-Mass.) to FDA commissioner-nominee Mark McClellan, MD/PhD. "Should it be a priority for FDA to evaluate this exciting new technology?" Kennedy asks. "Pathogen inactivation may prove valuable as an approach to reducing risk in blood products," McClellan replies. "These approaches, however, must be carefully evaluated for their immediate and long-term safety," he cautions...